Prediction of drug combination chemosensitivity in human bladder cancer.
about
Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function.Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration.Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell linesTarget inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathwaysDo breast cancer cell lines provide a relevant model of the patient tumor methylome?RREB1 transcription factor splice variants in urologic cancer.Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapyPersonalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.Data mining in genomicsBiomarkers for bladder cancer management: present and future.Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.Intra- and interspecies gene expression models for predicting drug response in canine osteosarcomaDrug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Pharmacogenomics in bladder cancer.Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway.Molecular markers in bladder cancer: Novel research frontiers.An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor.Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.Bladder cancer pharmacogenomics: recent insights and future perspectives.
P2860
Q24645336-61CF3EED-E899-4649-B66B-5E1201B1E7B8Q28291731-E9407AD2-AFC6-4C75-99CD-E842CACCBDD2Q28477988-36B60D52-99F5-44EF-BB42-B78167433C85Q28533401-6FBB53A7-7AA1-4338-B3B3-A3500E9E8940Q28542556-9EB1905A-59AB-4081-B278-C53D9192660AQ30426139-AE131B73-C78B-4CED-9E8B-020A0C98D4EDQ30430515-08F964A9-F6D1-43A3-9903-FD9A5D44209DQ30433023-97C40980-96ED-46DE-8AC2-9EBF3D224AF6Q30433465-22C66F6F-78B9-4A08-94CA-03C244803441Q30434260-D980576F-E3B0-46A3-84BA-D4C3CF3B03DDQ30437629-30D32143-997F-45C8-9424-B9C044264A95Q30438089-0E0026BC-539A-49A8-AC8D-2E428EA488AFQ30440132-64685A3B-72DB-46D0-9E52-A72D80606C13Q34448168-1CED3B36-DA8C-464D-BC2D-E65000C8455AQ35402899-B1708E8D-5BD8-415C-A1AC-2965846D8DA0Q35927860-7E1B3B11-CE88-463F-88DC-9B8D1030203AQ36406956-7F224658-0E89-43FF-94DE-0186361CE9D5Q37478633-C90BD348-764F-4E37-9930-89D62490FD1BQ37523551-079D2764-D29C-44EC-9AD5-E58313F31FC5Q37593264-01F32C15-AFB1-4997-9C29-75A72595A631Q38520403-1BC2104F-56C3-4632-8D8C-FFC8CE8F4308Q39623151-2BEDC6DB-A4A9-4C15-A10B-5836208F03EBQ39995744-FF2BD2B8-4AFE-4AF0-883E-A45BF7D35EF1Q51540087-38E62F7E-05E6-4313-B15E-16A6840B039E
P2860
Prediction of drug combination chemosensitivity in human bladder cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Prediction of drug combination chemosensitivity in human bladder cancer.
@ast
Prediction of drug combination chemosensitivity in human bladder cancer.
@en
type
label
Prediction of drug combination chemosensitivity in human bladder cancer.
@ast
Prediction of drug combination chemosensitivity in human bladder cancer.
@en
prefLabel
Prediction of drug combination chemosensitivity in human bladder cancer.
@ast
Prediction of drug combination chemosensitivity in human bladder cancer.
@en
P2093
P1476
Prediction of drug combination chemosensitivity in human bladder cancer.
@en
P2093
Charles R Owens
Dan Theodorescu
Dmytro M Havaleshko
Garret Hampton
HyungJun Cho
Mark Conaway
P304
P356
10.1158/1535-7163.MCT-06-0497
P577
2007-02-01T00:00:00Z